4SC and Yakult Honsha Announce Exclusive License Agreement for Japan for the Oral HDAC Inhibitor Resminostat

20-Apr-2011 - Germany

4SC AG and Yakult Honsha Co.; Ltd. announced the grant of an exclusive license by 4SC to Yakult Honsha for the development and commercialization of resminostat in Japan. Resminostat, an oral, pan-histone deacetylase (HDAC) inhibitor, is currently being evaluated in Phase II trials by 4SC in hepatocellular carcinoma (HCC), Hodgkin lymphoma (HL) and colorectal cancer in KRAS-mutant patients (CRC). Yakult Honsha will develop and commercialise resminostat primarily in HCC, CRC and retains the rights to develop and commercialise resminostat in other oncology indications in Japan.

4SC will receive an upfront payment from Yakult Honsha of EUR6 million and up to EUR127 million payable upon achieving specified milestones including clinical and regulatory events in Japan. In addition to milestone payments, Yakult will pay 4SC double-digit royalties linked to product sales of resminostat, which will also include the API costs. 4SC will be the exclusive supplier of resminostat to Yakult Honsha. Yakult Honsha will be responsible for all development and clinical requirements in Japan for resminostat in HCC, CRC and other chosen oncology indications.

Other news from the department research and development

Most read news

More news from our other portals

Fighting cancer: latest developments and advances